Literature DB >> 24675106

Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.

V Schneider1, L Zhang2, L Bullinger1, M Rojewski3, S Hofmann1, M Wiesneth3, H Schrezenmeier3, M Götz1, U Botzenhardt1, T F E Barth4, K Döhner1, H Döhner1, J Greiner5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24675106     DOI： 10.1038/leu.2014.116

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

Review 1.  Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells.

Authors:  R Majeti
Journal:  Oncogene       Date:  2010-11-15       Impact factor: 9.867

2.  Mutated regions of nucleophosmin 1 elicit both CD4(+) and CD8(+) T-cell responses in patients with acute myeloid leukemia.

Authors:  Jochen Greiner; Yoko Ono; Susanne Hofmann; Anita Schmitt; Elmar Mehring; Marlies Götz; Philippe Guillaume; Konstanze Döhner; Joannis Mytilineos; Hartmut Döhner; Michael Schmitt
Journal:  Blood       Date:  2012-05-16       Impact factor: 22.113

3.  Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut).

Authors:  Jochen Greiner; Vanessa Schneider; Michael Schmitt; Marlies Götz; Konstanze Döhner; Markus Wiesneth; Hartmut Döhner; Susanne Hofmann
Journal:  Blood       Date:  2013-08-08       Impact factor: 22.113

4.  Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.

Authors:  Susanne Hofmann; Marlies Götz; Vanessa Schneider; Philippe Guillaume; Donald Bunjes; Hartmut Döhner; Markus Wiesneth; Jochen Greiner
Journal:  J Clin Oncol       Date:  2012-12-17       Impact factor: 44.544

5.  A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

Authors:  Jonathan M Gerber; B Douglas Smith; Brownhilda Ngwang; Hao Zhang; Milada S Vala; Laura Morsberger; Steven Galkin; Michael I Collector; Brandy Perkins; Mark J Levis; Constance A Griffin; Saul J Sharkis; Michael J Borowitz; Judith E Karp; Richard J Jones
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

Review 6.  IL-12 family cytokines: immunological playmakers.

Authors:  Dario A A Vignali; Vijay K Kuchroo
Journal:  Nat Immunol       Date:  2012-07-19       Impact factor: 25.606

7.  Direct inhibition of human acute myeloid leukemia cell growth by IL-12.

Authors:  Elisa Ferretti; Emma Di Carlo; Claudia Cocco; Domenico Ribatti; Carlo Sorrentino; Emanuela Ognio; Daniela Montagna; Vito Pistoia; Irma Airoldi
Journal:  Immunol Lett       Date:  2010-08-10       Impact factor: 3.685

8.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 9.  Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.

Authors:  S Anguille; V F Van Tendeloo; Z N Berneman
Journal:  Leukemia       Date:  2012-06-01       Impact factor: 11.528

Review 10.  Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells.

Authors:  Jochen Greiner; Lars Bullinger; Barbara-ann Guinn; Hartmut Döhner; Michael Schmitt
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531
View more
  6 in total

1.  Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Authors:  Jochen Greiner; Susanne Hofmann; Michael Schmitt; Marlies Götz; Markus Wiesneth; Hubert Schrezenmeier; Donald Bunjes; Hartmut Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

2.  Leukemia Stem Cell Frequency at Diagnosis Correlates With Measurable/Minimal Residual Disease and Impacts Survival in Adult Acute Myeloid Leukemia.

Authors:  Azza M Kamel; Nahla M Elsharkawy; Eman Z Kandeel; Marwa Hanafi; Mohammed Samra; Randa A Osman
Journal:  Front Oncol       Date:  2022-04-08       Impact factor: 5.738

3.  Neutrophil extracellular traps arm DC vaccination against NPM-mutant myeloproliferation.

Authors:  Claudio Tripodo; Barbara Bassani; Mario P Colombo; Sabina Sangaletti; Elena Jachetti; Valeria Cancila; Claudia Chiodoni; Paola Portararo; Laura Botti; Cesare Valenti; Milena Perrone; Maurilio Ponzoni; Patrizia Comoli; Mara Lecchi; Paolo Verderio; Antonio Curti
Journal:  Elife       Date:  2022-04-26       Impact factor: 8.713

Review 4.  Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications.

Authors:  P Sportoletti; E Varasano; R Rossi; A Mupo; E Tiacci; G Vassiliou; M P Martelli; B Falini
Journal:  Leukemia       Date:  2014-09-02       Impact factor: 11.528

Review 5.  Neoantigens in Hematologic Malignancies.

Authors:  Melinda A Biernacki; Marie Bleakley
Journal:  Front Immunol       Date:  2020-02-14       Impact factor: 7.561

Review 6.  Increasing Role of Targeted Immunotherapies in the Treatment of AML.

Authors:  Jochen Greiner; Marlies Götz; Verena Wais
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.